CN Stock MarketDetailed Quotes

300204 Staidson

Watchlist
  • 8.40
  • -0.32-3.67%
Market Closed Nov 29 15:00 CST
4.01BMarket Cap-17987P/E (TTM)

About Staidson Company

The company was founded in August 2002 and listed on the Shenzhen Stock Exchange GEM on April 15, 2011. The company's main business is R&D, production and marketing of innovative drugs, especially biopharmaceuticals, with independent intellectual property rights. The company's main products are the innovative biological drug threeptiscene (mouse nerve growth factor for injection) and the specialty product sultaiqing (compound polyethylene glycol electrolyte powder (IV)). The company received honors such as the Beijing Economic and Technological Development Zone's top 50 tax payment growth enterprises in 2011, high-tech enterprises in Beijing, innovative pilot enterprises in the Zhongguancun National Independent Innovation Demonstration Zone, and the third prize of the Beijing Science and Technology Progress Award.

Company Profile

Short Name-A舒泰神
Symbol-A300204
Company NameStaidson (Beijing) Biopharmaceuticals Co., Ltd.
Listing DateApr 15, 2011
Issue Price52.50
Shares Offered16.70M share(s)
FoundedAug 16, 2002
Legal Representativezhiwen zhou
General Managerchao wang
Secretarymaorong yu
Accounting FirmTianheng Certified Public Accountants (Special General Partnership)
Securities Representativehan cai
Legal CounselBeijing Kangda Law Firm
Employees512
Phone010-67875255
Office AddressNo. 36, Jinghai 2nd Road, Beijing Economic and Technological Development Zone, Beijing
Zip Code100176
Registered AddressNo. 36, Jinghai 2nd Road, Beijing Economic and Technological Development Zone, Beijing
Fax010-67875255
Emailsecurities@staidson.com
Websitehttp://www.staidson.com
Business License110302004270284
BusinessProduction of tablets, hard capsules, powders, oral solutions, and therapeutic biological products (pharmaceutical production license is valid until December 7, 2025); technology development, technology transfer, technical consulting, technical services for pharmaceuticals and biological products; import and export of goods, agency import and export, technology import and export. (Market players independently select business projects and carry out business activities in accordance with the law; projects subject to approval according to law carry out business activities according to the approved content after approval by the relevant departments; they are not allowed to engage in business activities for projects prohibited or restricted by national and local industrial policies.)

Company Executives

  • Name
  • Position
  • Salary
  • zhiwen zhou
  • Chairman, Directors, Chairman of the Strategy Committee
  • 1.30M
  • rongqin zhang
  • Directors, Strategy Committee Member, Member of the Remuneration and Assessment Committee
  • 1.70M
  • lianchun yang
  • Directors, Strategy Committee Member, Nomination Committee Members, Audit Committee Member
  • 1.60M
  • xiaoyan wang
  • Directors
  • --
  • qishun lu
  • Independent Directors, Nomination Committee Members, Chairman of the Audit Committee
  • --
  • li zhao
  • Independent Directors, Strategy Committee Member, Chairman of the Remuneration and Assessment Committee, Audit Committee Member
  • 136.80K
  • jiajun zhao
  • Independent Directors, Chairman of the Nomination Committee, Strategy Committee Member, Member of the Remuneration and Assessment Committee
  • 136.80K
  • maorong yu
  • Board Secretary, Deputy General Manager
  • 733.50K
  • han cai
  • Securities Affairs Representative
  • --
  • hongshan zhang
  • Chairman of the Supervisory Board, Auditors
  • 900.00K
  • tao li
  • Auditors
  • 600.00K
  • chao wang
  • General Manager, Head of Finance
  • 1.36M
  • shicheng li
  • Chief Financial Officer
  • 980.10K
  • yujing feng
  • Director of Internal Audit
  • 477.00K
  • yanfang sun
  • Chief Engineer
  • 272.00K
  • hong zheng
  • Employee Supervisors
  • 588.10K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
% Chg

No Data